Mirova US’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$339M Sell
368,438
-15,836
-4% -$16.1M 3.85% 7
2025
Q4
$413M Buy
384,274
+3,607
+0.9% +$3.45M 4.15% 6
2025
Q3
$290M Sell
380,667
-14,588
-4% -$10.9M 2.93% 13
2025
Q2
$308M Sell
395,255
-215,500
-35% -$167M 3.19% 12
2025
Q1
$504M Buy
610,755
+20,834
+4% +$17.3M 5.99% 4
2024
Q4
$455M Sell
589,921
-18,023
-3% -$14.9M 5.46% 4
2024
Q3
$539M Buy
607,944
+5,015
+0.8% +$4.51M 6.18% 4
2024
Q2
$546M Buy
602,929
+12,634
+2% +$10.1M 6.8% 3
2024
Q1
$459M Sell
590,295
-10,671
-2% -$7.59M 6.17% 5
2023
Q4
$350M Sell
600,966
-89,499
-13% -$52.2M 5.28% 9
2023
Q3
$371M Buy
690,465
+26,151
+4% +$13.5M 6.29% 7
2023
Q2
$312M Buy
664,314
+16,207
+3% +$6.8M 5.19% 9
2023
Q1
$223M Buy
648,107
+7,556
+1% +$2.55M 4.04% 12
2022
Q4
$234M Sell
640,551
-197,584
-24% -$70.1M 4.71% 9
2022
Q3
$271M Sell
838,135
-3,572
-0.4% -$1.13M 6.33% 4
2022
Q2
$273M Buy
841,707
+50,381
+6% +$15.1M 5.88% 6
2022
Q1
$227M Buy
791,326
+62,343
+9% +$16M 4.35% 12
2021
Q4
$201M Buy
728,983
+152,493
+26% +$38.7M 3.78% 12
2021
Q3
$133M Buy
576,490
+62,815
+12% +$15.5M 3.11% 14
2021
Q2
$118M Buy
513,675
+58,796
+13% +$11.8M 3.16% 13
2021
Q1
$85M Buy
+454,879
New +$89M 2.96% 14

Other funds holding LLY

Mirova US's LLY Position: Q1 2026 in Review

Mirova US reduced its Eli Lilly (LLY) stake by 4.1% in Q1 2026, selling an estimated $16.1M and leaving 368,438 shares worth $339M. The position accounts for 3.85% of the portfolio, ranked #7.

Mirova US first reported a position in LLY in Q1 2021 and has held it in 21 quarters since. The position peaked at $546M in Q2 2024. 4,352 funds tracked by Wall St. Rank hold LLY as of Q1 2026.

  • Mirova US held 368,438 shares of Eli Lilly worth $339M as of Q1 2026.
  • Mirova US sold 15,836 Eli Lilly shares in Q1 2026, an estimated $16.1M.
  • Eli Lilly made up 3.85% of Mirova US's portfolio in Q1 2026, its #7 holding.
  • Mirova US first reported a position in Eli Lilly in Q1 2021 and has held it in 21 quarters since.
  • Mirova US's Eli Lilly position peaked at $546M in Q2 2024.
  • 4,352 funds tracked by Wall St. Rank held Eli Lilly as of Q1 2026.

Based on Mirova US's 13F filing for Q1 2026, filed 11 May 2026.